{ "schema_version": "1.0", "source": "trials", "data_as_of": "2026-09-09T03:06:49.777Z", "selected_count": 28, "sampled": false, "records": [ { "source": "trials", "source_id": "NCT07663903", "title": "Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment", "summary": "The indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII).\n\nThe primary objective:\n\nEvaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand treatment in previously treated patients with severe hemophilia A.\n\nSecondary objectives:\n\nEvaluation of the safety and immunogenicity of FRSW107 as an on-demand therapy in previously treated patients with severe hemophilia A.\n\nEvaluate the on-demand treatment's PK profile of FRSW107 in previously treated patients with severe hemophilia A based on population pharmacokinetic (PopPK) methods ; preliminarily investigate the exposure-response (E-R) relationship of FRSW107 on-demand treatment in these patients if data permit.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07663903", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Hangzhou Gensciences Biopharmaceutical Co., Ltd.", "enrollment": { "count": 60, "type": "ESTIMATED" }, "primary_completion": { "date": "2027-02", "type": "ESTIMATED" }, "conditions": [ "Severe Hemophilia A" ], "interventions": [ { "type": "DRUG", "name": "FRSW107", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT07596199", "title": "A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women", "summary": "The purpose of this Phase 3, non-randomized, single-arm, open-label study is to evaluate the immune response, reactogenicity and safety of GSKs dTpa vaccine in Japanese pregnant women between 27 weeks and less than 37 weeks of pregnancy. Both the pregnant women and their neonates born during the study will be evaluated for specific analyses.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07596199", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "GlaxoSmithKline", "enrollment": { "count": 102, "type": "ACTUAL" }, "primary_completion": { "date": "2026-11-23", "type": "ESTIMATED" }, "conditions": [ "Diphtheria-Tetanus-acellular Pertussis Vaccines" ], "interventions": [ { "type": "BIOLOGICAL", "name": "dTpa", "other_names": [ "Boostrix" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT07495813", "title": "A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease", "summary": "This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07495813", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Hoffmann-La Roche", "enrollment": { "count": 196, "type": "ESTIMATED" }, "primary_completion": { "date": "2026-10-30", "type": "ESTIMATED" }, "conditions": [ "Stable Coronary Artery Disease", "Healthy Volunteers" ], "interventions": [ { "type": "DRUG", "name": "RO7763505", "other_names": [] }, { "type": "DRUG", "name": "Placebo", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT07400653", "title": "A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)", "summary": "The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in the blood.\n\nThe study medicine is given by a shot under the skin in the belly area. The participants will be trained to do this at home once every week.\n\nAbout 660 out of 1000 adults will also receive the study medicine and about 330 out of 1000 adults will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help us assess if the study medicine is safe and effective.\n\nPeople will take part in this study for about 21 months. During this time, they will have about 14 study visits at the site and 5 over the phone.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07400653", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Pfizer", "enrollment": { "count": 1078, "type": "ACTUAL" }, "primary_completion": { "date": "2027-10-12", "type": "ESTIMATED" }, "conditions": [ "Obesity", "Overweight and/or Obesity", "Overweight", "Diabetes, Type 2", "Type 2 Diabetes" ], "interventions": [ { "type": "DRUG", "name": "PF-08653944", "other_names": [ "MET097" ] }, { "type": "OTHER", "name": "Placebo", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT07308392", "title": "Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis", "summary": "Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07308392", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Fujian Shengdi Pharmaceutical Co., Ltd.", "enrollment": { "count": 119, "type": "ACTUAL" }, "primary_completion": { "date": "2027-06", "type": "ESTIMATED" }, "conditions": [ "Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis" ], "interventions": [ { "type": "DRUG", "name": "HRS-7249 injection set", "other_names": [] }, { "type": "DRUG", "name": "SHR-1918 injection set", "other_names": [] }, { "type": "DRUG", "name": "HRS-7249 injection placebo set", "other_names": [] }, { "type": "DRUG", "name": "SHR-1918 injection placebo set", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT07027527", "title": "An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis", "summary": "The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07027527", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Apogee Therapeutics, Inc.", "enrollment": { "count": 86, "type": "ACTUAL" }, "primary_completion": { "date": "2026-08-29", "type": "ACTUAL" }, "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "type": "DRUG", "name": "APG777", "other_names": [] }, { "type": "DRUG", "name": "APG990", "other_names": [] }, { "type": "DRUG", "name": "Dupilumab", "other_names": [ "Dupixent" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "summary": "The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT07005128", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Amgen", "enrollment": { "count": 350, "type": "ACTUAL" }, "primary_completion": { "date": "2029-01-04", "type": "ESTIMATED" }, "conditions": [ "Small-cell Lung Cancer", "Extensive Stage Small-cell Lung Cancer" ], "interventions": [ { "type": "DRUG", "name": "Tarlatamab", "other_names": [ "AMG 757", "Imdelltra" ] }, { "type": "DRUG", "name": "Durvalumab", "other_names": [] }, { "type": "DRUG", "name": "Carboplatin", "other_names": [] }, { "type": "DRUG", "name": "Etoposide", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT06973304", "title": "A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome", "summary": "The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral support and understand how the body absorbs, processes, and gets rid of teduglutide.\n\nParticipants will receive a daily injection of teduglutide under the skin for 24 weeks. Safety of teduglutide will be checked for 24 weeks after treatment.\n\nParticipants will be in the study for about 65 weeks.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT06973304", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Takeda", "enrollment": { "count": 13, "type": "ACTUAL" }, "primary_completion": { "date": "2027-02-10", "type": "ESTIMATED" }, "conditions": [ "Short Bowel Syndrome" ], "interventions": [ { "type": "DRUG", "name": "Teduglutide", "other_names": [ "TAK-633", "A16AX08", "Revestive", "Gattex" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT06764485", "title": "A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer", "summary": "The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT06764485", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Celgene", "enrollment": { "count": 960, "type": "ESTIMATED" }, "primary_completion": { "date": "2027-09-12", "type": "ESTIMATED" }, "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "type": "DRUG", "name": "BMS-986365", "other_names": [] }, { "type": "DRUG", "name": "Enzalutamide", "other_names": [] }, { "type": "DRUG", "name": "Abiraterone", "other_names": [] }, { "type": "DRUG", "name": "Docetaxel", "other_names": [] }, { "type": "DRUG", "name": "Predinsone/Prednisolone", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT06625060", "title": "A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults", "summary": "A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers.\n\nParticipants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. \"Headache days\" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. \"Migraine days\" occur when the headache displays clear migraine characteristics.\n\nThis study aims to determine:\n\n* The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM,\n* The right amount (dose) of Corabotase to inject at each point,\n* The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines.\n\nParticipants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT06625060", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Ipsen", "enrollment": { "count": 670, "type": "ACTUAL" }, "primary_completion": { "date": "2027-10-31", "type": "ESTIMATED" }, "conditions": [ "Episodic Migraine", "Chronic Migraine" ], "interventions": [ { "type": "BIOLOGICAL", "name": "Corabotase", "other_names": [] }, { "type": "OTHER", "name": "Placebo", "other_names": [] }, { "type": "BIOLOGICAL", "name": "Corabotase dose A", "other_names": [] }, { "type": "BIOLOGICAL", "name": "Corabotase dose B", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT06567769", "title": "Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)", "summary": "The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT06567769", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "GC Biopharma Corp", "enrollment": { "count": 9, "type": "ESTIMATED" }, "primary_completion": { "date": "2027-06", "type": "ESTIMATED" }, "conditions": [ "Sanfilippo Syndrome Type A" ], "interventions": [ { "type": "DRUG", "name": "GC1130A", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT06539338", "title": "A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment", "summary": "The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained.\n\nINT2104 is a gene therapy delivering a transgene for a chimeric antigen receptor (CAR) specific for CD20 (CAR20). The lentiviral vector is designed to generate CAR T and CAR Natural Killer (NK) cells inside the body following intravenous (IV) administration.\n\nStudy details include the following:\n\n* The study duration will be 5 years\n* The treatment duration will be a one-time intravenous (IV) infusion of INT2104", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT06539338", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Kite, A Gilead Company", "enrollment": { "count": 10, "type": "ACTUAL" }, "primary_completion": { "date": "2026-10", "type": "ESTIMATED" }, "conditions": [ "Lymphomas Non-Hodgkin's B-Cell", "Precursor Cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "type": "GENETIC", "name": "INT2104", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT05857930", "title": "A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing", "summary": "This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT05857930", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "OM Pharma SA", "enrollment": { "count": 296, "type": "ACTUAL" }, "primary_completion": { "date": "2026-09-30", "type": "ESTIMATED" }, "conditions": [ "Recurrent Wheezing", "Wheezing Lower Respiratory Illness" ], "interventions": [ { "type": "DRUG", "name": "OM-85", "other_names": [] }, { "type": "DRUG", "name": "Placebo", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT05801029", "title": "A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations", "summary": "This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT05801029", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "AstraZeneca", "enrollment": { "count": 60, "type": "ACTUAL" }, "primary_completion": { "date": "2027-10-01", "type": "ESTIMATED" }, "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "type": "DRUG", "name": "Osimertinib", "other_names": [] }, { "type": "DRUG", "name": "Amivantamab", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT05668741", "title": "A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)", "summary": "The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT05668741", "metadata": { "phase": [ "PHASE1", "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Vertex Pharmaceuticals Incorporated", "enrollment": { "count": 26, "type": "ACTUAL" }, "primary_completion": { "date": "2026-04-21", "type": "ACTUAL" }, "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "type": "DRUG", "name": "VX-522 mRNA therapy", "other_names": [] }, { "type": "DRUG", "name": "IVA", "other_names": [ "ivacaftor", "VX-770" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT05502315", "title": "Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer", "summary": "This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT05502315", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Rana McKay, MD", "enrollment": { "count": 47, "type": "ESTIMATED" }, "primary_completion": { "date": "2026-10-12", "type": "ESTIMATED" }, "conditions": [ "Castration-resistant Prostate Cancer", "Metastatic Cancer" ], "interventions": [ { "type": "DRUG", "name": "Cabozantinib", "other_names": [ "Cabometyx" ] }, { "type": "DRUG", "name": "Nivolumab", "other_names": [ "Opdivo" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT05108259", "title": "To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects", "summary": "The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502 to the European (EU) and American (US) Humira reference products, following a single subcutaneous (SC) dose of 40 mg in healthy volunteers.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT05108259", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Prestige Biopharma Limited", "enrollment": { "count": 160, "type": "ESTIMATED" }, "primary_completion": { "date": "2027-06", "type": "ESTIMATED" }, "conditions": [ "Healthy Volunteers" ], "interventions": [ { "type": "DRUG", "name": "PBP1502", "other_names": [ "Adalimumab" ] }, { "type": "DRUG", "name": "EU-licensed Humira", "other_names": [ "Adalimumab" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT05047172", "title": "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis", "summary": "The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT05047172", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "University of Florida", "enrollment": { "count": 1683, "type": "ESTIMATED" }, "primary_completion": { "date": "2027-01-31", "type": "ESTIMATED" }, "conditions": [ "Intracranial Arteriosclerosis", "Stroke" ], "interventions": [ { "type": "DRUG", "name": "Ticagrelor + Aspirin", "other_names": [ "Brilinta" ] }, { "type": "DRUG", "name": "Rivaroxaban + Aspirin", "other_names": [ "Xarelto" ] }, { "type": "DRUG", "name": "Clopidogrel + Aspirin", "other_names": [ "Plavix" ] }, { "type": "OTHER", "name": "Risk Factor Management", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT04821089", "title": "A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines", "summary": "The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines.\n\nThis study will be conducted in three stages. The full study (including all stages) will have a maximum 727 participants.\n\nStage 1 (phase Ib \\& II)\n\n* Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL)\n* Step 2 (Phase II): dose ranging step in participants with moderate to severe GL as compared with Dysport\n* Step 3 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport, followed by an open label (OL) phase for the highest dose cohort to assess the long-term safety and efficacy of Corabotase. In the OL phase, participants may receive repeat administrations of Corabotase for up to three additional cycles (up to four treatment cycles in total during the study).\n\nStage 2 (phase II) - An evaluation of efficacy and safety of Corabotase in one of the following regions: GL + forehead lines (FHL), forehead lines (FHL) or lateral canthal lines (LCL)\n\nStage 3 (phase II)\n\n\\- A safety and efficacy evaluation of Corabotase in all three regions (GL, FHL and LCL)", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT04821089", "metadata": { "phase": [ "PHASE1", "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Ipsen", "enrollment": { "count": 727, "type": "ESTIMATED" }, "primary_completion": { "date": "2026-08-31", "type": "ESTIMATED" }, "conditions": [ "Moderate to Severe Upper Facial Lines" ], "interventions": [ { "type": "BIOLOGICAL", "name": "Corabotase", "other_names": [] }, { "type": "BIOLOGICAL", "name": "IPN10200 Placebo", "other_names": [] }, { "type": "BIOLOGICAL", "name": "Dysport", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT04695080", "title": "ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis", "summary": "MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide.\n\nWithout disease modifying treatment (DMT),the majority of people with MS (pwMS) will develop significant disability within 10 years of onset, and 50% will require wheelchair assistance within 20 years. convenient, highly effective and CNS penetrant DMT for patients with relapsing multiple sclerosis (pwRMS) administered in short (8-10 days/year over 2 years) treatment courses.\n\nIt effectively depletes B cells, particularly Memory B cells, a likely key mechanism of disease control in MS. Cladribine is the investigational product in this study as it not currently used to treat patients with an EDSS of 6.5 - 8.5. This is a multi-centre, randomised double-blind placebo-controlled phase IIb to test cladribine tablets (MAVENCLAD®) (3.5mg/kg over 24 months) for safety, efficacy, and cost effectiveness, and to advance mechanistic understanding of its action in people with advanced MS (pwAMS).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT04695080", "metadata": { "phase": [ "PHASE2", "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Queen Mary University of London", "enrollment": { "count": 204, "type": "ACTUAL" }, "primary_completion": { "date": "2027-12-31", "type": "ESTIMATED" }, "conditions": [ "Advanced Multiple Sclerosis", "Progressive Multiple Sclerosis" ], "interventions": [ { "type": "DRUG", "name": "Cladribine (MAVENCLAD®)", "other_names": [] }, { "type": "DRUG", "name": "Placebo", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT04534205", "title": "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1", "summary": "An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.\n\nThis trial has two parts.\n\nPart A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.\n\nPart B, is a randomized part to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Patients included in the Safety Run-In Phase of the trial (Part A) will not be randomized to Part B and will continue on-trial treatment (BNT113 plus pembrolizumab) within Part A.\n\nFor Part B, an optional pre-screening phase is available for all patients where patients' tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing prior to screening into the main trial.\n\nPatients will be treated with BNT113 in combination with pembrolizumab or with pembrolizumab monotherapy for approximately up to 24 months.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT04534205", "metadata": { "phase": [ "PHASE2", "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "BioNTech SE", "enrollment": { "count": 358, "type": "ACTUAL" }, "primary_completion": { "date": "2028-08", "type": "ESTIMATED" }, "conditions": [ "Unresectable Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Cancer", "Recurrent Head and Neck Cancer" ], "interventions": [ { "type": "BIOLOGICAL", "name": "BNT113", "other_names": [] }, { "type": "BIOLOGICAL", "name": "Pembrolizumab", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03897881", "title": "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)", "summary": "The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03897881", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "ModernaTX, Inc.", "enrollment": { "count": 267, "type": "ACTUAL" }, "primary_completion": { "date": "2032-11-21", "type": "ESTIMATED" }, "conditions": [ "Melanoma" ], "interventions": [ { "type": "DRUG", "name": "mRNA-4157", "other_names": [] }, { "type": "BIOLOGICAL", "name": "Pembrolizumab", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03875287", "title": "Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors", "summary": "This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal hypomethylation and toxicity (up to 35 patients total).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03875287", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "enrollment": { "count": 35, "type": "ESTIMATED" }, "primary_completion": { "date": "2027-03-02", "type": "ESTIMATED" }, "conditions": [ "Solid Tumor" ], "interventions": [ { "type": "DRUG", "name": "Decitabine", "other_names": [ "Dacogen" ] }, { "type": "DRUG", "name": "Cedazuridine", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03731234", "title": "Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance", "summary": "This is a prospective, multicenter, single arm, phase II trial in patients with ≥ 18 and \\<65 years with poor-prognosis (IPI ≥ 2) and newly diagnosed ABC-DLBCL.\n\nAim of the study is to assess the efficacy and the safety of R-CHOP in combination with ibrutinib for 6 cycles followed by ibrutinib maintenance for 18 months in ABC-DLBCL patients achieving at least a PR after the induction phase", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03731234", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Fondazione Italiana Linfomi - ETS", "enrollment": { "count": 75, "type": "ESTIMATED" }, "primary_completion": { "date": "2024-07-30", "type": "ACTUAL" }, "conditions": [ "DLBCL" ], "interventions": [ { "type": "DRUG", "name": "Ibrutinib", "other_names": [ "IMBRUVICA (commercial name)" ] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03708965", "title": "An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II", "summary": "A Phase II open-label, parallel group, 2 sites (Brazil), designed to evaluate the long term safety and efficacy of study drug for the treatment of the MPS II.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03708965", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "JCR Pharmaceuticals Co., Ltd.", "enrollment": { "count": 19, "type": "ACTUAL" }, "primary_completion": { "date": "2026-12-31", "type": "ESTIMATED" }, "conditions": [ "Mucopolysaccharidosis II" ], "interventions": [ { "type": "DRUG", "name": "JR-141", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03395197", "title": "Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC", "summary": "This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03395197", "metadata": { "phase": [ "PHASE3" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Pfizer", "enrollment": { "count": 1054, "type": "ACTUAL" }, "primary_completion": { "date": "2022-10-03", "type": "ACTUAL" }, "conditions": [ "mCRPC" ], "interventions": [ { "type": "DRUG", "name": "Talazoparib with enzalutamide", "other_names": [] }, { "type": "DRUG", "name": "Placebo with enzalutamide", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03122522", "title": "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy", "summary": "This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is sufficient for patients with early benefit compared to the usual way of trying to give 4 doses. If patients do not show early benefit after 2 doses, patients will be able to continue with additional ipilimumab + nivolumab, even beyond the standard 4 doses if felt in the best interest of the patient.", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03122522", "metadata": { "phase": [ "PHASE2" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Memorial Sloan Kettering Cancer Center", "enrollment": { "count": 70, "type": "ACTUAL" }, "primary_completion": { "date": "2027-04", "type": "ESTIMATED" }, "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "type": "DRUG", "name": "ipilimumab", "other_names": [] }, { "type": "DRUG", "name": "nivolumab", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" }, { "source": "trials", "source_id": "NCT03006172", "title": "To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer", "summary": "This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in patients with locally advanced or metastatic PIK3CA-mutant solid tumors, including breast cancer, and in combination with standard-of-care endocrine and/or targeted therapies for the treatment of locally advanced or metastatic PIK3CA-mutant breast cancer. Participants will be enrolled in two stages: a dose-escalation stage (Stage I) and an expansion stage (Stage II). Participants will be assigned to one of seven regimens: inavolisib as a single agent (Arm A), inavolisib in combination with palbociclib and letrozole (Arm B), inavolisib in combination with letrozole (Arm C), inavolisib in combination with fulvestrant (Arm D), inavolisib in combination with palbociclib and fulvestrant (Arm E), inavolisib in combination with palbociclib, fulvestrant, and metformin (Arm F), and inavolisib in combination with trastuzumab and pertuzumab (and letrozole or fulvestrant, if applicable (Arm G)).", "published_date": "2026-09-08", "url": "https://clinicaltrials.gov/study/NCT03006172", "metadata": { "phase": [ "PHASE1" ], "status": "ACTIVE_NOT_RECRUITING", "sponsor": "Genentech, Inc.", "enrollment": { "count": 200, "type": "ACTUAL" }, "primary_completion": { "date": "2026-12-31", "type": "ESTIMATED" }, "conditions": [ "Breast Cancer", "Solid Tumor" ], "interventions": [ { "type": "DRUG", "name": "Inavolisib", "other_names": [ "RO7113755, GDC-0077" ] }, { "type": "DRUG", "name": "Fulvestrant", "other_names": [] }, { "type": "DRUG", "name": "Letrozole", "other_names": [] }, { "type": "DRUG", "name": "Palbociclib", "other_names": [] }, { "type": "DRUG", "name": "Metformin", "other_names": [] }, { "type": "DRUG", "name": "Trastuzumab", "other_names": [] }, { "type": "DRUG", "name": "Pertuzumab", "other_names": [] } ] }, "fetched_at": "2026-09-09T03:06:49.777Z" } ], "next_cursor": null }